RIPK3 and Zika virus infectious disease: We further pre-treated the cells with GSK’872, an inhibitor of RIPK3, followed by ZIKV infection, and observed the morphological integrity change of the cells p.i. As shown in Figure 6B, the ZIKA-infected cells pre-treated with GSK’872 remained unchanged in morphology in comparison to the uninfected cells p.i. In contrast, the infected cells without GSK’872 treatment underwent necrotic deterioration and the monolayer started to deteriorate after infection, indicating that the ZIKV-induced necroptosis was suppressed effectively when RIPK3 was inhibited in the cells (Figure 6B, bottom).